Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Sep 15, 2009 (Vol. 29, No. 16)

Quebec Eyes Biotech as Key Growth Sector

Canada’s “Little City” Has Made a Big Investment in Biotechnology and It Seems To Be Paying Off

  • Economic Indicators and Incentives for Doing Business in Quebec City

    • Unemployment (1H09) = 4.8%
      (vs. 8.3% for Quebec Province and 8.0% for Canada)
    • Jobs (1H09) = +2,700 compared to 1H08
    • GDP (avg annual growth 1Q07–09) = 3.3% (vs. 0.7% for Quebec Province and 0.5% for Canada)
    • Per capita personal income growth (1Q07–09) = 4.9% (projected 2.8% in 2010)
    • Capital investment growth (2004–2009) = 47.4% (vs. 24.8% for Quebec Province)
    • Typical business start-up and operating costs = $14.06 million (vs. an average of $14.35 million for Canada and $15.19 million for the U.S.)
    • Effective tax rate for manufacturing companies = 30.90% (vs. 44.41% for New York and 40.75% for California)
    • Refundable tax credits include: 17.5% of R&D salaries paid in Quebec; 35% of eligible R&D expenditures at accredited research centers

Readers' Comments

Posted 10/08/2009 by The Canadian Biotechnologist2.0 Blog

Do visit this blog for ongoing coverage of this sector: http://cbt20.org.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »